Featured Research

from universities, journals, and other organizations

Fox Chase Cancer Center Offers Topical Gel To Treat Precursor To Skin Cancer

Date:
January 24, 2002
Source:
Fox Chase Cancer Center
Summary:
Individuals with parapsoriasis, a red, scaly rash located in the “bathing suit” area, could be at risk for developing a potentially deadly cancer. Researchers at Fox Chase Cancer Center are conducting an innovative clinical trial using bexarotene (Targretin®), a form of vitamin A in a topical gel, to treat parapsoriasis and prevent the disease from progressing into cancer.

PHILADELPHIA - Individuals with parapsoriasis, a red, scaly rash located in the “bathing suit” area, could be at risk for developing a potentially deadly cancer. Researchers at Fox Chase Cancer Center are conducting an innovative clinical trial using bexarotene (Targretin®), a form of vitamin A in a topical gel, to treat parapsoriasis and prevent the disease from progressing into cancer.

“What’s unique about this trial is that we are treating what is considered a precursor to cancer,” says Stuart Lessin, MD, director of the Dermatology Oncology Program at Fox Chase Cancer Center. A precursor acts as a warning sign alerting that the onset of cancer is imminent.

Parapsoriasis is a skin condition considered a precursor to cutaneous T-cell lymphoma, (CTCL) which is a potentially deadly form of cancer that manifests in the skin and targets the body’s white blood cells (lymphocytes), impairing the patient’s immune system. Despite its name, parapsoriasis differs from psoriasis in its appearance and location on the body. The skin condition starts as red, scaly rash that appears on the trunk of the body, instead of on the extremities.

“Parapsoriasis has a similar name to psoriasis, but it’s a very different disease,” says Lessin. “Parapsoriasis has the potential to progress to CTCL and differentiation between parapsoriasis and early stage CTCL can be difficult and often requires evaluation by an experienced specialist,” says Lessin.

Patients can live with the complications of CTCL long after the initial diagnosis and according to the Mycosis Fungoides Foundation, approximately 16,000 people in the United States are affected with the disease annually. CTCL slowly progresses from scaling skin patches to larger areas of thickened plaques and then to tumor nodules. In the late stages, the cancer grows to involve lymph nodes, blood and internal organs and most patients die from infections due to breakdown of the skin and a crippled immune system.

The FDA has approved Targretin® for the treatment of CTCL, but Lessin and his colleagues are using the gel as a prevention tool. “If we can treat patients who are diagnosed with parapsoriasis, we can potentially stop the cancer before it has a chance to start or progress,” says Lessin.

Bexarotene (Targretin®) is a unique type of retinoid, a synthetic form of vitamin A that binds to specific retinoid receptors and regulates cell function. The drug inhibits cancer growth and induces apoptosis, or programmed cell death.

Patients who are newly diagnosed with parapsoriasis or who have skin lesions suggestive of, but not diagnostic of CTCL, maybe eligible to participate in this clinical trial, which is only available at Fox Chase Cancer Center. In the trial, the topical gel is initially applied to the skin lesions everyday for two weeks, than twice a day for up to 16 weeks. Tissue from the skin lesions is taken or biopsied before and after treatment to determine response to the gel.

“We’re hoping that patients suffering from parapsoriasis will respond to the Targretin® therapy, whereby clearing up the uncomfortable condition, and preventing further progression of the disease,” Lessin said. The trial is sponsored by Ligand Pharmaceuticals Incorporated makers of Targretin®.

Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at http://www.fccc.edu or call 1-888-FOX CHASE.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "Fox Chase Cancer Center Offers Topical Gel To Treat Precursor To Skin Cancer." ScienceDaily. ScienceDaily, 24 January 2002. <www.sciencedaily.com/releases/2002/01/020123075821.htm>.
Fox Chase Cancer Center. (2002, January 24). Fox Chase Cancer Center Offers Topical Gel To Treat Precursor To Skin Cancer. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2002/01/020123075821.htm
Fox Chase Cancer Center. "Fox Chase Cancer Center Offers Topical Gel To Treat Precursor To Skin Cancer." ScienceDaily. www.sciencedaily.com/releases/2002/01/020123075821.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) — Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins